[Financial and Operational Highlights](index=1&type=section&id=Financial%20and%20Operational%20Highlights) Aemetis reported increased Q2 2025 revenue to $52.2 million, driven by India biodiesel and Dairy RNG, alongside strategic biogas and India IPO preparations Q2 2025 Key Financial Metrics | Metric | Value ($) | Note | | :--- | :--- | :--- | | **Revenues** | $52.2M | Increased $9.3M from Q1 2025 | | **Aemetis Biogas Revenue** | $3.1M | From 11 operating digesters | | **Operating Loss** | Improved by $4.9M | Compared to Q1 2025, due to lower SG&A | - The increase in revenue was primarily driven by the California Ethanol and Dairy RNG segments, along with new orders for the India Biodiesel business from Oil Marketing Companies[3](index=3&type=chunk)[5](index=5&type=chunk) - Strategic developments include the appointment of a new CFO for the India subsidiary, targeting a public listing in early **2026**[5](index=5&type=chunk) - Aemetis Biogas signed a **$27 million** agreement with NPL for H₂S and compression units for **15** dairy digesters and received CARB approval for **7** new LCFS pathways[5](index=5&type=chunk) - The company anticipates increased income and cash flow from Section 45Z production tax credits and cost reductions from the mechanical vapor recompression project in its California Ethanol segment[3](index=3&type=chunk)[4](index=4&type=chunk) [Financial Results](index=2&type=section&id=Financial%20Results) Aemetis reported Q2 2025 revenues of $52.2 million, a decrease from Q2 2024, but improved operating and net losses for both the quarter and first half [Financial Results for the Three Months Ended June 30, 2025](index=2&type=section&id=Financial%20Results%20for%20the%20Three%20Months%20Ended%20June%2030%2C%202025) Q2 2025 revenues decreased to $52.2 million year-over-year, while operating and net losses improved to $10.7 million and $23.4 million respectively, despite a wider gross loss Q2 2025 vs Q2 2024 Financial Comparison | Metric | Q2 2025 ($) | Q2 2024 ($) | Change ($) | | :--- | :--- | :--- | :--- | | **Revenues** | $52.2M | $66.6M | ($14.4M) | | **Gross Loss** | ($3.4M) | ($1.8M) | ($1.6M) | | **Operating Loss** | ($10.7M) | ($13.6M) | $2.9M Improvement | | **Net Loss** | ($23.4M) | ($29.2M) | $5.8M Improvement | - SG&A expenses decreased significantly to **$7.3 million** from **$11.8 million** year-over-year, primarily due to a one-time **$3.6 million** loss on asset disposals in 2024[7](index=7&type=chunk) - Cash at quarter-end was **$1.6 million**, up from **$900 thousand** at the end of 2024, with **$3.6 million** invested in capital projects during the quarter[10](index=10&type=chunk) [Financial Results for the Six Months Ended June 30, 2025](index=2&type=section&id=Financial%20Results%20for%20the%20Six%20Months%20Ended%20June%2030%2C%202025) H1 2025 revenues decreased to $95.1 million due to India contract delays, while gross and operating losses widened, but net loss improved to $47.9 million H1 2025 vs H1 2024 Financial Comparison | Metric | H1 2025 ($) | H1 2024 ($) | Change ($) | | :--- | :--- | :--- | :--- | | **Revenues** | $95.1M | $139.2M | ($44.1M) | | **Gross Loss** | ($8.4M) | ($2.4M) | ($6.0M) | | **Operating Loss** | ($26.2M) | ($23.1M) | ($3.1M) | | **Net Loss** | ($47.9M) | ($53.4M) | $5.5M Improvement | - The lower revenue in H1 2025 was primarily due to delays in receiving contracts from government-owned Oil Marketing Companies in India[11](index=11&type=chunk) - Total investments in capital projects during H1 2025 amounted to **$5.4 million**, with **$4.1 million** dedicated to Aemetis Biogas projects[14](index=14&type=chunk) [Company Overview and Forward-Looking Statements](index=2&type=section&id=Company%20Overview%20and%20Forward-Looking%20Statements) Aemetis is a renewable energy company producing RNG, fuels, and biochemicals, with operations in California and India, and developing SAF, while reporting non-GAAP measures and forward-looking statements - Aemetis operates a California biogas digester network (RNG), a **65 MGY** ethanol plant in California, an **80 MGY** biodiesel facility in India, and is developing a SAF/renewable diesel biorefinery[15](index=15&type=chunk)[16](index=16&type=chunk) - The company defines Adjusted EBITDA as net loss adjusted for interest, taxes, depreciation, amortization, accretion, and share-based compensation[17](index=17&type=chunk) - The release contains forward-looking statements regarding growth plans, market trends, project development, and capital raising, subject to various risks and uncertainties[19](index=19&type=chunk) [Consolidated Financial Statements](index=4&type=section&id=Consolidated%20Financial%20Statements) This section presents unaudited consolidated financial statements, detailing Q2 and H1 2025 operations, and the balance sheet as of June 30, 2025, showing asset and liability changes [Consolidated Condensed Statements of Operations](index=4&type=section&id=CONSOLIDATED%20CONDENSED%20STATEMENTS%20OF%20OPERATIONS) Aemetis reported a net loss of $23.4 million for Q2 2025 and $47.9 million for H1 2025, showing improvement compared to prior-year periods, with a Q2 2025 loss per share of $0.41 Consolidated Condensed Statements of Operations (unaudited, in thousands, except per share data) | | For the three months ended June 30, (in thousands) | For the six months ended June 30, (in thousands) | | :--- | :--- | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | **Revenues** | $52,243 | $66,561 | $95,129 | $139,195 | | Cost of goods sold | 55,598 | 68,367 | 103,564 | 141,613 | | **Gross loss** | **(3,355)** | **(1,806)** | **(8,435)** | **(2,418)** | | SG&A expenses | 7,319 | 11,800 | 17,794 | 20,650 | | **Operating loss** | **(10,674)** | **(13,606)** | **(26,229)** | **(23,068)** | | Interest expense | 12,330 | 11,724 | 26,023 | 22,237 | | Accretion of Series A preferred units | 2,032 | 3,477 | 4,311 | 6,788 | | **Net loss** | **$(23,395)** | **$(29,174)** | **$(47,924)** | **$(53,405)** | | **Net loss per common share (Basic & Diluted)** | **$(0.41)** | **$(0.66)** | **$(0.87)** | **$(1.24)** | [Consolidated Condensed Balance Sheets](index=5&type=section&id=CONSOLIDATED%20CONDENSED%20BALANCE%20SHEETS) As of June 30, 2025, Aemetis reported total assets of $240.0 million, total liabilities of $529.3 million, and a stockholders' deficit of $289.3 million, with a notable increase in current long-term debt Consolidated Condensed Balance Sheets (in thousands) | | June 30, 2025 (Unaudited, in thousands) | December 31, 2024 (in thousands) | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $1,645 | $898 | | Total current assets | $20,086 | $44,696 | | Property, plant and equipment, net | $204,641 | $199,392 | | **Total assets** | **$240,016** | **$259,302** | | **Liabilities and Stockholders' Deficit** | | | | Current portion of long term debt | $247,615 | $63,745 | | Total current liabilities | $321,927 | $143,968 | | Total long term liabilities | $207,344 | $379,262 | | Total stockholders' deficit | $(289,255) | $(263,928) | | **Total liabilities and stockholders' deficit** | **$240,016** | **$259,302** | [Non-GAAP Reconciliation and Operational Metrics](index=6&type=section&id=Non-GAAP%20Reconciliation%20and%20Operational%20Metrics) This section presents non-GAAP Adjusted EBITDA reconciliation and operational metrics, showing a slight improvement in Q2 2025 Adjusted EBITDA loss and varied production volumes across segments [Reconciliation of Adjusted EBITDA to Net Income/(Loss)](index=6&type=section&id=RECONCILIATION%20OF%20ADJUSTED%20EBITDA%20TO%20NET%20INCOME%2F%28LOSS%29) Aemetis reported an Adjusted EBITDA loss of $5.8 million for Q2 2025, a slight improvement, but a $16.4 million loss for H1 2025, a deterioration, with reconciliation details provided Reconciliation of Adjusted EBITDA to Net Loss (unaudited, in thousands) | | For the three months ended June 30, (in thousands) | For the six months ended June 30, (in thousands) | | :--- | :--- | :--- | :--- | :--- | | | **2025** | **2024** | **2025** | **2024** | | **Net loss** | **$(23,395)** | **$(29,174)** | **$(47,924)** | **$(53,405)** | | Total adjustments | 17,627 | 23,268 | 31,494 | 42,749 | | **Adjusted EBITDA** | **$(5,768)** | **$(5,906)** | **$(16,430)** | **$(10,656)** | [Production and Price Performance](index=7&type=section&id=PRODUCTION%20AND%20PRICE%20PERFORMANCE) Q2 2025 production and sales varied by segment, with California Ethanol volumes decreasing, Dairy RNG increasing, and India Biodiesel sales significantly dropping due to contract delays Q2 2025 vs Q2 2024 Production and Sales Comparison | Segment | Metric | Q2 2025 (Units) | Q2 2024 (Units) | | :--- | :--- | :--- | :--- | | **California Ethanol** | Gallons sold (millions) | 13.8 | 14.8 | | **CA Dairy RNG** | MMBtu sold (thousands) | 106.4 | 88.0 | | **India Biodiesel** | Metric tons sold (thousands) | 9.4 | 20.4 | Q2 2025 vs Q2 2024 Average Price Comparison | Segment | Metric | Q2 2025 ($) | Q2 2024 ($) | | :--- | :--- | :--- | :--- | | **California Ethanol** | Avg. sales price/gallon | $2.01 | $1.99 | | **CA Dairy RNG** | Avg. price per MMBtu | $2.75 | $2.19 | | **India Biodiesel** | Avg. sales price/metric ton | $1,010 | $1,162 |

Exhibit 99.1 FOR IMMEDIATE RELEASE Contact: KVH Industries, Inc. Chris Watson 401-845-2441 IR@kvh.com KVH Industries Reports Second Quarter 2025 Results MIDDLETOWN, RI, August 7, 2025 — KVH Industries, Inc. (Nasdaq: KVHI), reported financial results for the quarter ended June 30, 2025 today. The company will hold a conference call to discuss these results at 9:00 a.m. ET today, which can be accessed at investors.kvh.com. Following the call, a replay of the webcast will be available through the company's web ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) 321 Arsenal Street, Suite 101 Watertown, Massachusetts 02472 (Address of principal executive offices) (Zip Code) Delaware 85-1612845 (I.R. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 PLAYTIKA HOLDING CORP. (Exact Name of Registrant as Specified in its Charter) Delaware 81-3634591 (State of other jurisdiction (I.R.S. Employer of incorporation or organization) Identification No.) c/o Playtika Ltd. HaChoshlim St 8 Herzliya Pituach, Israel 972-73-316-3251 (Address, including zip code, and telephone number, includ ...

Exhibit 99.1 Disc Medicine Reports Second Quarter 2025 Financial Results and Provides Business Update WATERTOWN, Mass., August 7, 2025 – Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a recap of recent program and corporate developments. "We are please ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission file number 1-03480 MDU RESOURCES GROUP, INC. (Exact name of registrant as specified in its charter) (Registrant's telephone nu ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-37872 Priority Technology Holdings, Inc. (Exact name of registrant as specified in its charter) Delaware 47-4257046 (State or other jurisdi ...

[PART I - FINANCIAL INFORMATION](index=5&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) [Item 1. Financial Statements (unaudited)](index=5&type=section&id=Item%201.%20Financial%20Statements%20(unaudited)) This section presents the unaudited condensed consolidated financial statements for Q2 and H1 2025, including balance sheets, operations, cash flows, and detailed notes [Condensed Consolidated Balance Sheets](index=5&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of June 30, 2025, total assets decreased to **$279.0 million** while total liabilities increased to **$218.1 million**, driven by operating lease liabilities Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $53,804 | $182,476 | | Total current assets | $121,287 | $211,886 | | Total assets | $279,009 | $297,508 | | **Liabilities & Stockholders' Equity** | | | | Total current liabilities | $34,109 | $37,961 | | Operating lease liability, net of current | $112,478 | $37,180 | | Total liabilities | $218,149 | $144,359 | | Total stockholders' equity | $60,860 | $153,149 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) Q2 2025 saw **$1.1 million** in revenue and a **$52.6 million** net loss, while H1 2025 net loss was **$104.5 million** Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Total revenue | $1,115 | $0 | $2,569 | $591 | | Research and development | $41,375 | $43,071 | $81,937 | $80,845 | | General and administrative | $13,117 | $12,601 | $26,401 | $23,759 | | Loss from operations | $(53,377) | $(55,672) | $(105,769) | $(104,013) | | Net loss | $(52,591) | $(55,327) | $(104,481) | $(101,088) | | Net loss per share | $(0.41) | $(0.46) | $(0.81) | $(0.90) | [Condensed Consolidated Statements of Cash Flows](index=9&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) H1 2025 net cash used in operating activities was **$90.3 million**, with financing activities providing **$6.2 million**, ending the period with **$67.5 million** in cash Cash Flow Summary for the Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(90,269) | $(113,198) | | Net cash used in investing activities | $(44,971) | $(30,138) | | Net cash provided by financing activities | $6,197 | $157,362 | | **Net change in cash, cash equivalents, and restricted cash** | **$(129,043)** | **$14,026** | | Cash, cash equivalents, and restricted cash at end of period | $67,495 | $69,096 | [Notes to Condensed Consolidated Financial Statements](index=11&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) These notes detail liquidity, accounting policies, and key agreements, including a **$138.2 million** stock offering, stock option repricing, and ongoing arbitration with Beam Therapeutics - In August 2025, the company raised approximately **$138.2 million** in net proceeds from a common stock offering, which is expected to be sufficient to fund operations for at least the next twelve months[34](index=34&type=chunk)[35](index=35&type=chunk) - On August 1, 2025, the company repriced certain outstanding employee and director stock options with exercise prices above **$4.04** down to **$4.04** per share to improve retention and incentive value[80](index=80&type=chunk)[81](index=81&type=chunk) - The company is in an arbitration proceeding with Beam Therapeutics, Inc regarding a dispute over the development of a treatment for alpha-1 antitrypsin deficiency (AATD)[89](index=89&type=chunk)[141](index=141&type=chunk) - In July 2025, the company entered into an agreement with the Cystic Fibrosis Foundation (CFF) for up to **$24 million** in additional funding to accelerate the development of Prime Editors for cystic fibrosis[87](index=87&type=chunk) [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=24&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the strategic shift to the in vivo liver franchise, analyzes Q2 and H1 2025 financial results, and highlights a **$138.2 million** financing extending the cash runway into 2027 [Overview and Business Update](index=27&type=section&id=Overview%20and%20Business%20Update) The company strategically refocused on its in vivo liver franchise (Wilson's Disease, AATD) with 2026 IND/CTA filings, while continuing CF and CAR-T programs and seeking partners for PM359 - Strategic focus has shifted to the in vivo liver franchise, targeting Wilson's Disease and AATD, with IND/CTA filings anticipated in the first half and middle of 2026, respectively[94](index=94&type=chunk) - The company will continue its Cystic Fibrosis program, supported by up to **$24 million** in additional funding from the Cystic Fibrosis Foundation, and its CAR-T collaboration with Bristol-Myers Squibb[95](index=95&type=chunk)[96](index=96&type=chunk) - Initial data from the Phase 1/2 trial of PM359 for CGD showed high levels of dihydrorhodamine positivity, considered potentially curative; the company is now seeking partners for this program following its strategic shift[97](index=97&type=chunk) [Results of Operations](index=29&type=section&id=Results%20of%20Operations) Q2 2025 R&D expenses decreased by **$1.7 million** due to program deprioritization, while H1 2025 G&A expenses increased by **$2.6 million** from severance and legal fees R&D Expense Comparison - Q2 (in thousands) | Category | Q2 2025 | Q2 2024 | Change | | :--- | :--- | :--- | :--- | | Personnel expenses | $14,448 | $16,198 | $(1,750) | | Facility related | $13,765 | $11,302 | $2,463 | | Research costs | $8,116 | $11,390 | $(3,274) | | **Total R&D expenses** | **$41,375** | **$43,071** | **$(1,696)** | G&A Expense Comparison - H1 (in thousands) | Category | H1 2025 | H1 2024 | Change | | :--- | :--- | :--- | :--- | | Personnel expenses | $14,238 | $12,840 | $1,398 | | Professional and consultant fees | $7,228 | $5,931 | $1,297 | | **Total G&A expenses** | **$26,401** | **$23,759** | **$2,642** | - The decrease in Q2 R&D spending was driven by a **$3.3 million** reduction in research costs and a **$1.1 million** drop in clinical expenses due to the deprioritization of the CGD program[107](index=107&type=chunk) - The increase in H1 G&A expenses was primarily due to a **$1.4 million** increase in personnel costs related to one-time severance payments from the workforce reduction and a **$1.3 million** increase in corporate legal fees[112](index=112&type=chunk)[116](index=116&type=chunk) [Liquidity and Capital Resources](index=34&type=section&id=Liquidity%20and%20Capital%20Resources) As of June 30, 2025, the company held **$101.8 million** in cash and investments, supplemented by a **$138.2 million** August 2025 stock offering, extending its cash runway into 2027 - As of June 30, 2025, the company held **$101.8 million** in cash, cash equivalents, and investments[117](index=117&type=chunk) - An August 2025 stock offering generated approximately **$138.2 million** in net proceeds, extending the company's cash runway into 2027[118](index=118&type=chunk)[126](index=126&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=32&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company's primary market risk is interest rate sensitivity on its **$115.4 million** investment portfolio, though a 10% rate change is not expected to be material - The company is exposed to interest rate risk on its **$115.4 million** portfolio of cash, cash equivalents, investments, and restricted cash[135](index=135&type=chunk) - Management does not believe a 10% change in interest rates would materially affect the fair market value of its investments due to their short-term nature[135](index=135&type=chunk) [Item 4. Controls and Procedures](index=33&type=section&id=Item%204.%20Controls%20and%20Procedures) As of June 30, 2025, the company's disclosure controls and procedures were effective, with no material changes to internal control over financial reporting during Q2 2025 - The company's disclosure controls and procedures were deemed effective as of the end of the period covered by this report (June 30, 2025)[138](index=138&type=chunk) - No changes occurred during the quarter that have materially affected, or are reasonably likely to materially affect, the company's internal control over financial reporting[139](index=139&type=chunk) [PART II - OTHER INFORMATION](index=34&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) [Item 1. Legal Proceedings](index=34&type=section&id=Item%201.%20Legal%20Proceedings) The company is in arbitration with Beam Therapeutics over alleged breach of a collaboration agreement regarding the AATD program, with Beam seeking damages and program transfer - The company is in a consolidated arbitration proceeding with Beam Therapeutics regarding the development of a treatment for AATD[141](index=141&type=chunk) - Beam alleges breach of contract and seeks declaratory, injunctive, and monetary relief, which could include forcing the company to cease work on its AATD program and transfer it to Beam[141](index=141&type=chunk) [Item 1A. Risk Factors](index=34&type=page&id=Item%201A.%20Risk%20Factors) Updated risk factors include healthcare reform, U.S. tax/trade policy changes, challenges in retaining key personnel, collaborator disputes, and operational risks from the May 2025 restructuring - Healthcare reform, including the Inflation Reduction Act of 2022 (IRA), could increase costs, add downward pressure on drug prices, and adversely affect profitability[143](index=143&type=chunk)[147](index=147&type=chunk) - The company's ability to retain key employees is a significant risk, exacerbated by a declining stock price that has left many stock options "underwater"; a recent option repricing was implemented to address this[158](index=158&type=chunk)[160](index=160&type=chunk) - The ongoing arbitration with Beam Therapeutics is highlighted as a material risk, as an adverse outcome could result in monetary damages and the loss of the company's AATD program[163](index=163&type=chunk) - The May 2025 strategic restructuring and workforce reduction may not achieve anticipated cost savings and could disrupt operations, reduce morale, and lead to further attrition[164](index=164&type=chunk)[165](index=165&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=39&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) No unregistered sales of equity securities occurred during the three months ended June 30, 2025 - There were no unregistered sales of equity securities in the three months ended June 30, 2025[167](index=167&type=chunk) [Item 5. Other Information](index=39&type=section&id=Item%205.%20Other%20Information) No directors or officers adopted, modified, or terminated Rule 10b5-1 trading plans during the three months ended June 30, 2025 - No directors or officers adopted, modified, or terminated a Rule 10b5-1 trading plan during the quarter[171](index=171&type=chunk) [Item 6. Exhibits](index=40&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Quarterly Report on Form 10-Q, including officer certifications and various agreements

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 1-31923 (IRS Employer Identification No.) 4225 East Windrose Drive, Suite 200 Phoenix, Arizona 85032 (Address of principal ...

Exhibit 99.1 QT Imaging Announces Continuous Strong Revenue Growth and Enhanced Balance Sheet in the Second Quarter 2025 Announces New 'QTI Cloud Platform' as it Accelerates Its Transformation into a Precision Imaging AI Company NOVATO, CA – Aug 7, 2025 – QT Imaging Holdings, Inc. (OTCQB: QTIH) ("QT Imaging" or the "Company"), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the three and six months end ...